Tirabrutinib: Ph II started

Gilead began a double-blind, placebo-controlled, international Phase II trial to evaluate 200 mg oral filgotinib (GLPG0634, GS-6034), 30 mg oral GS-9876 or 40 mg oral tirabrutinib each alone once dail...